1 |
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-983.
DOI
|
2 |
Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001;47:1985-1992.
|
3 |
Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008;31:1473-1478.
DOI
|
4 |
Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278.
DOI
|
5 |
Kim HJ, Kim YG, Park JS, Ahn YH, Ha KH, Kim DJ. Association between blood glucose level derived using the oral glucose tolerance test and glycated hemoglobin level. Korean J Intern Med 2016;31:535-542.
DOI
|
6 |
Chalew SA, Hempe JM, McCarter R. Clinically significant disagreement between mean blood glucose and estimated average glucose in two populations: implications for diabetes management. J Diabetes Sci Technol 2009;3:1128-1135.
DOI
|
7 |
Hempe JM, Soros AA, Chalew SA. Estimated average glucose and self-monitored mean blood glucose are discordant estimates of glycemic control. Diabetes Care 2010;33:1449-1451.
DOI
|
8 |
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Wilson DM, Xing D, et al. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care 2011;34:540-544.
DOI
|
9 |
Munshi MN, Segal AR, Slyne C, Samur AA, Brooks KM, Horton ES. Shortfalls of the use of HbA1C-derived eAG in older adults with diabetes. Diabetes Res Clin Pract 2015;110:60-65.
DOI
|
10 |
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
DOI
|
11 |
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
DOI
|
12 |
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
DOI
|
13 |
Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 2008;51:921-925.
DOI
|
14 |
Yong YM, Shin KM, Lee KM, et al. Intensive individualized reinforcement education is important for the prevention of hypoglycemia in patients with type 2 diabetes. Diabetes Metab J 2015;39:154-163.
DOI
|
15 |
Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J 2015;39:273-282.
DOI
|
16 |
Koga M. 1,5-Anhydroglucitol and glycated albumin in glycemia. Adv Clin Chem 2014;64:269-301.
|
17 |
Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761-1773.
DOI
|
18 |
American Diabetes Association. 5. Glycemic targets. Diabetes Care 2016;39 Suppl 1:S39-S46.
DOI
|
19 |
Ko SH, Kim SR, Kim DJ, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-436.
DOI
|
20 |
Wolffenbuttel BH, Herman WH, Gross JL, Dharmalingam M, Jiang HH, Hardin DS. Ethnic differences in glycemic markers in patients with type 2 diabetes. Diabetes Care 2013;36:2931-2936.
DOI
|